FAB's CTO, Noah Berlow, is Combining Biology & Engineering to Speed Drug Development (Nature)

Moving drugs to and through phased trials, especially in cancer, is daunting and riddled with complexity. By combining engineering and biology, First Ascent Biomedical & partner, Children's Cancer Therapy Development Institute, have repeatedly demonstrated their process more effectively drives informed decisions for pharmaceutical companies, significantly reducing time and costs.


First Ascent Bio has created commercial success with this process by helping pharma partners (including Roche, GSK, Prelude, Blueprint & others) to find and refine biomarkers, speeding their drug development timelines, with the goal of reducing their 9 in 10 failure rate of clinical trials.


Read the full article in Nature (May 2022) here:

https://www.nature.com/articles/d41586-022-01513-5


13 views0 comments

Recent Posts

See All